| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | FIMM | pan-cancer | AAC | 0.72 | 5e-07 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.14 | 0.0002 |
| mRNA | BIBW2992 | FIMM | pan-cancer | AAC | 0.53 | 0.0003 |
| mRNA | AZD0530 | CTRPv2 | pan-cancer | AAC | 0.16 | 0.0003 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0005 |
| mRNA | SMER-3 | CTRPv2 | pan-cancer | AAC | -0.15 | 0.0006 |
| mRNA | Gefitinib | FIMM | pan-cancer | AAC | 0.52 | 0.0006 |
| mRNA | KIN001-055 | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0007 |
| mRNA | Vandetanib | FIMM | pan-cancer | AAC | 0.56 | 0.0009 |
| mRNA | VAF-347 | CTRPv2 | pan-cancer | AAC | 0.19 | 0.001 |